• Dr. Richard E. Chaisson

    January 1, 1970 pendari Committees

    Richard E. Chaisson, M.D., Chair of the Tuberculosis Transformative Science Group for the AIDS Clinical Trials Group (ACTG) Network, is Professor of Medicine, Epidemiology and International Health at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health in Baltimore, MD, USA. From 1988-1998 he was director of the Johns Hopkins AIDS Service, and he co-founded with Richard Moore the Johns Hopkins HIV Clinic Cohort, an observational cohort study that has made seminal contributions to understanding the outcomes of HIV disease and its treatment. 

    Dr. Chaisson is founder and director of the Johns Hopkins Center for Tuberculosis Research, a multidisciplinary institute dedicated to the study of TB from bench to bedside to community. His research interests focus on tuberculosis and HIV infection, including global epidemiology, clinical trials, diagnostics, and public health interventions.  He is also principal investigator and director of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB at the population level, including active case finding and widespread use of TB preventive therapy. He maintains active collaborative research and training programs in Brazil, South Africa, Malawi, Lesotho, and India. Most recently he assumed leadership of the Johns Hopkins Center for AIDS Research (CFAR), re-establishing and revitalizing a trans-disciplinary program to catalyze innovative HIV research at Hopkins, with a special focus on combatting the Baltimore epidemic. He has published over 400 scientific papers and book chapters.
    Read more

  • Dr. John Mellors

    January 1, 1970 pendari Committees

    [Spotlight originally posted October, 2011]

    Dr. Mellors is the Chief of Infectious Diseases at the University of Pittsburgh and tenured Professor of Medicine. He is principal investigator of the NIH-funded Pittsburgh AIDS Clinical Trials Unit, and director of the Virology Core Laboratories for the AIDS Clinical Trials Group Network and the Microbicide Trials Network.

    Dr. Mellors’ research is dedicated to preventing, treating, and seeking a cure for HIV infection. His past work provided critical insight into the relation between viremia and HIV disease progression. His laboratory has focused on HIV resistance to antiretroviral drugs, which is a major obstacle to effective therapy. His laboratory’s work in this area has helped define the genetic and biochemical basis for HIV resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors of HIV-1 reverse transcriptase, and the clinical impact of such resistance. More recent research projects are focusing on preventing HIV-1 infection through the use of antiretrovirals and quantifying HIV reservoirs in patients on antiretroviral therapy with the long-term goal of eliminating them.

    Read more

  • Dr. Eric S. Daar

    January 1, 1970 pendari Committees

    [Spotlight originally posted October, 2011]

    Dr. Daar is Principal Investigator of the Harbor-UCLA Medical Center Clinical Research Site and the Chair of the Antiretroviral Strategies Subcommittee.  He is the Chief of the Division of HIV Medicine at Harbor-UCLA Medical Center and Professor of Medicine at the David Geffen School of Medicine.    He is an active clinician and investigator with active participation on several ACTG committees and protocol teams.  His research interests include the management of HIV-1 infection and its complications, the immunopathogenesis of primary and chronic HIV-1 infection, and HIV neuropathogenesis.

    Read more